Drug pricing is supposed to be a mystery—until you look at the math.
Most people hear “cost-plus” and think it’s a policy slogan. But the real story is more uncomfortable for the industry: cost-plus pricing is a spotlight. It forces the conversation aw…

Mark Cuban’s generic drug play isn’t just another healthcare headline—it’s a stress test for the entire patent-and-pricing machine.
Here’s the agitation: for decades, the U.S. drug market has rewarded incumbents with a predictable rhythm—patent protect…

Biotech hiring isn’t just about headcount. It’s about signals.
When a company starts posting roles—especially in licensing, BD, legal ops, regulatory strategy, and “business development with a scientific lens”—it often means something is moving behind …

Patent cliffs aren’t just a legal event. They’re a pricing strategy.
If you’ve watched the pharmaceutical industry long enough, you know the script: a blockbuster’s patent protection nears expiration, generic competition looms, and revenue growth bec…

Drug pricing transparency is one of those ideas that sounds so virtuous it’s almost impossible to argue against—until you look at what it actually does to the incentives that keep medicines coming.
The industry is now being pushed toward a world where …

Big Pharma vs. Cost-Plus isn’t a debate—it’s a modeling problem.
Mark Cuban’s Cost Plus Drugs has become the latest flashpoint in the U.S. drug pricing war. But if you’re an investor, operator, policy professional, or healthcare strategist, the real …

Pharma doesn’t “guess” when the next patent cliff is coming. It tracks it—down to the day.
In the race to secure global patent extensions, the winners aren’t just the companies with the best science. They’re the companies with the best systems: the one…

Pharma doesn’t just “watch” patent dates—it operationalizes them.
In the race to secure market exclusivity, the difference between winning and losing can come down to a handful of days: an IND filing milestone, an NDA submission window, a regulatory re…

Europe’s “divisional patent” trap is one of those legal mechanisms that sounds technical—until you see what it does to patients, payers, and timelines.
Here’s the uncomfortable truth: Big Pharma can often delay generic entry without “losing in court.” …

Generic drug approvals aren’t just about filing a dossier—they’re about proving the body will treat your product the same way.
That’s the real game behind complex generics, and it’s why bioequivalence strategy has become the decisive differentiator b…